| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20050998 | HPV | ENSG00000122025.15 | protein_coding | FLT3 | Yes | No | 2322 | P36888 |
| TVIS20065483 | HPV | ENSG00000122025.15 | protein_coding | FLT3 | Yes | No | 2322 | P36888 |
| TVIS44031243 | HTLV-1 | ENSG00000122025.15 | protein_coding | FLT3 | Yes | No | 2322 | P36888 |
| TVIS44008044 | HTLV-1 | ENSG00000122025.15 | protein_coding | FLT3 | Yes | No | 2322 | P36888 |
| TVIS44020668 | HTLV-1 | ENSG00000122025.15 | protein_coding | FLT3 | Yes | No | 2322 | P36888 |
| TVIS44036283 | HTLV-1 | ENSG00000122025.15 | protein_coding | FLT3 | Yes | No | 2322 | P36888 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | FLT3 |
|---|---|
| DrugBank ID | DB11800 |
| Drug Name | Tivozanib |
| Target ID | BE0000147 |
| UniProt ID | P36888 |
| Regulation Type | inhibitor |
| PubMed IDs | 31496820; 24019545 |
| Citations | Yalcin S, Lacin S: Impact of tivozanib on patient outcomes in treatment of advanced renal cell carcinoma. Cancer Manag Res. 2019 Aug 16;11:7779-7785. doi: 10.2147/CMAR.S206105. eCollection 2019.@@Motzer RJ, Nosov D, Eisen T, Bondarenko I, Lesovoy V, Lipatov O, Tomczak P, Lyulko O, Alyasova A, Harza M, Kogan M, Alekseev BY, Sternberg CN, Szczylik C, Cella D, Ivanescu C, Krivoshik A, Strahs A, Esteves B, Berkenblit A, Hutson TE: Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol. 2013 Oct 20;31(30):3791-9. doi: 10.1200/JCO.2012.47.4940. Epub 2013 Sep 9. |
| Groups | Approved; Investigational |
| Direct Classification | Diarylethers |
| SMILES | COC1=C(OC)C=C2C(OC3=CC(Cl)=C(NC(=O)NC4=NOC(C)=C4)C=C3)=CC=NC2=C1 |
| Pathways | |
| PharmGKB | |
| ChEMBL | CHEMBL1289494 |
